Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Bulletin Du Cancer|July 9, 2011
[Cell cycle and molecular targets: CDK inhibition]Philippe Carassou, Laurent Meijer, Sylvestre Le Moulec, et al.
Presse Medicale (Paris, France : 1983)|April 20, 2010
[Respiratory manifestations of giant cell arteritis: 8 cases and review of the literature]Philippe Carassou, Marc Aletti, Gaël Cinquetti, et al.
The American Journal of Case Reports|March 5, 2021
A 50-Year-Old Man with Fulminant Alpha-Fetoprotein-Producing Gastric Carcinoma and Disseminated Intravascular CoagulationRaffaele Longo, Philippe Carassou, Cassandre Leguay, et al.
The American Journal of Case Reports|April 24, 2025
Multiple Myeloma Presenting as Breast Metastasis: Diagnostic Challenges and Case AnalysisGloria Messina, Maria Antonia Fucile, Marianne Kupper, et al.
Human Mutation|April 1, 2020
TAR syndrome: Clinical and molecular characterization of a cohort of 26 patients and description of novel noncoding variants of RBM8ASimon Boussion, Fabienne Escande, Anne-Sophie Jourdain, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.
Pageof 1